Idorsia is launching a late-stage trial of the experimental heart-attack drug selatogrel that the Swiss company hopes will become what it describes as akin to an “EpiPen” for people at risk of acute myocardial infarction (AMI).

The U.S. Food and Drug Administration approved a prefilled syringe for self-injection of the allergic diseases treatment Xolair developed by Novartis and Genentech, a Roche company.